Avalo Therapeutics Inc (AVTX)

$17.57 -0.35 (-1.95%)
Market Cap 235.68M
Revenue (ttm) 440,000.00
Net Income (ttm) -35.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,984.09%
Debt to Equity Ratio 0.00
Volume 516,800
Avg Vol 357,210
Day's Range N/A - N/A
Shares Out 13.15M
Stochastic %K 70%
Beta 0.93
Analysts Strong Sell
Price Target $33.67

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 522 8707
Address:
540 Gaither Road, Suite 400, Rockville, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AVTX Current Share Price: $17.76 Contracts: $AVTX May 15, 2026 $20 Calls Scale in: $5.11- $6.24 Scale out: $7.94-$10.21 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Toffeepanda
Toffeepanda Oct. 24 at 10:14 PM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 12:02 PM
$AVTX 🤣 ok i take it 29 %
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 11:31 AM
$AVTX Cantor #Biotechnology: Today @ 2 PM ET - Panel Discussion with Leading Dermatologists $AVTX $PTGX
0 · Reply
sccp1910
sccp1910 Oct. 24 at 10:49 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 10:15 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 8:01 PM
$AVTX
0 · Reply
WallGoodman
WallGoodman Oct. 23 at 2:28 PM
$AVTX your welcome..
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 2:26 PM
$AVTX i remember the days wen vol was 3k a day🤣
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 2:22 PM
$AVTX why is this not tren ding 🤣
0 · Reply
Latest News on AVTX
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Sep 22, 2025, 7:00 AM EDT - 4 weeks ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Aug 18, 2025, 8:30 AM EDT - 2 months ago

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 7, 2025, 7:00 AM EDT - 2 months ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Jun 18, 2025, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025, 7:00 AM EDT - 5 months ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 26, 2025, 7:00 AM EDT - 7 months ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Mar 25, 2025, 3:20 PM EDT - 7 months ago

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Avalo Reports 2024 Financial Results and Recent Business Updates

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 9 months ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Jan 2, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 24, 2024, 4:01 PM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 17, 2024, 7:30 AM EDT - 1 year ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 7:30 AM EDT - 1 year ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Apr 1, 2024, 6:02 AM EDT - 1 year ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 29, 2024, 4:01 PM EDT - 1 year ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 27, 2023, 7:00 AM EST - 1 year ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Avalo Completes Divestiture of AVTX-800 Series

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Avalo to Participate in SVB Securities Therapeutics Forum

Jul 6, 2023, 4:01 PM EDT - 2 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Avalo to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the Jefferies Healthcare Conference

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

May 22, 2023, 7:00 AM EDT - 2 years ago

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D.

Avalo to Present at ATS 2023 Respiratory Innovation Summit

May 15, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at ATS 2023 Respiratory Innovation Summit

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 2 years ago

Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

May 4, 2023, 4:01 PM EDT - 2 years ago

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Avalo Reports 2022 Financial Results and Provides Business Updates

Mar 29, 2023, 7:30 AM EDT - 2 years ago

Avalo Reports 2022 Financial Results and Provides Business Updates

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Mar 7, 2023, 7:00 AM EST - 2 years ago

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Feb 2, 2023, 9:54 PM EST - 2 years ago

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Feb 2, 2023, 4:01 PM EST - 2 years ago

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Jan 17, 2023, 7:00 AM EST - 3 years ago

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 7, 2022, 7:30 AM EST - 3 years ago

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Nov 7, 2022, 7:00 AM EST - 3 years ago

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:28 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AVTX Current Share Price: $17.76 Contracts: $AVTX May 15, 2026 $20 Calls Scale in: $5.11- $6.24 Scale out: $7.94-$10.21 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Toffeepanda
Toffeepanda Oct. 24 at 10:14 PM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 12:02 PM
$AVTX 🤣 ok i take it 29 %
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 11:31 AM
$AVTX Cantor #Biotechnology: Today @ 2 PM ET - Panel Discussion with Leading Dermatologists $AVTX $PTGX
0 · Reply
sccp1910
sccp1910 Oct. 24 at 10:49 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 24 at 10:15 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 8:01 PM
$AVTX
0 · Reply
WallGoodman
WallGoodman Oct. 23 at 2:28 PM
$AVTX your welcome..
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 2:26 PM
$AVTX i remember the days wen vol was 3k a day🤣
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 2:22 PM
$AVTX why is this not tren ding 🤣
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 2:18 PM
$VKTX $AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 1:45 PM
$AVTX
0 · Reply
CaptainCoin3
CaptainCoin3 Oct. 23 at 1:41 PM
$AVTX TO THE MOOOOON!!!
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 11:20 AM
$AVTX
0 · Reply
ret0258
ret0258 Oct. 23 at 11:17 AM
$AVTX 20+
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 10:47 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 23 at 10:30 AM
$AVTX
0 · Reply
Trapjaw
Trapjaw Oct. 22 at 1:59 PM
$AVTX
0 · Reply
mikesterz7
mikesterz7 Oct. 22 at 11:37 AM
$AVTX Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.
1 · Reply
Trapjaw
Trapjaw Oct. 22 at 9:48 AM
$AVTX
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 22 at 8:51 AM
GIPR has optionality baked in. Real estate gives downside protection. A story shift (tokenization of assets, digital‑asset holdings, lease re‑ratings) gives upside. At current levels, the range up to $10+, even $13+, starts feeling very plausible when the market recognizes it. $VCIG $AVTX $YOSH $KPRX
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 22 at 8:12 AM
Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug $AVTX https://stocktwits.com/news/equity/markets/avalo-therapeutics-stock-rises-premarket-ahead-of-oppenheimer-call-on-lead-hidradenitis-drug/cLG5chVR3pw
1 · Reply